Actuate Therapeutics, Inc. (ACTU)
| Market Cap | 16.98M -89.2% |
| Revenue (ttm) | n/a |
| Net Income | -20.45M |
| EPS | -0.89 |
| Shares Out | 24.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,260 |
| Open | 0.7380 |
| Previous Close | 0.7362 |
| Day's Range | 0.6832 - 0.7479 |
| 52-Week Range | 0.6042 - 8.4900 |
| Beta | 0.96 |
| Analysts | Strong Buy |
| Price Target | 11.68 (+1,551.58%) |
| Est. Earnings | Nov 12, 2026 |
About ACTU
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apothe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ACTU stock is "Strong Buy." The 12-month stock price target is $11.68, which is an increase of 1,551.58% from the latest price.
News
Actuate Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Oral elraglusib is advancing to clinical trials, aiming to improve outcomes in metastatic pancreatic and other cancers by enhancing patient exposure and enabling synergistic combinations with RAS inhibitors. The program includes a robust pediatric strategy and is supported by strong clinical, preclinical, and regulatory progress.
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on develop...
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on develop...
Actuate Therapeutics Quarterly report: Q2 2026
Actuate Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Actuate Therapeutics Slides: Corporate presentation
Actuate Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Actuate Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Michael King initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $6 price target
Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham - Elraglusib ...
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients ...
Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital
Lucid Capital lowered the firm’s price target on Actuate Therapeutics (ACTU) to $5 from $6 and keeps a Buy rating on the shares. The firm updated the company’s model post…
Actuate Therapeutics Quarterly report: Q1 2026
Actuate Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Actuate Therapeutics receives FDA clearance for oral elraglusib study
Actuate Therapeutics (ACTU) announced the FDA has cleared its investigational new drug application to conduct a Phase 1/2 study of oral elraglusib in advanced cancer patients. The study is designed…
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on m...
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies Martin Huber, MD brings deep expertise in oncology drug development, ...
Actuate Therapeutics Proxy statement: Proxy filing
Actuate Therapeutics filed a proxy statement on May 6, 2026, providing details for shareholder voting and corporate governance matters.
Actuate Therapeutics management to meet with B. Riley
Meeting to be held in Dallas on May 5 hosted by B. Riley.
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actuate Therapeutics with chemotherapy were alive after one year as those treated with chemo alone, acco...
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developi...
Actuate Therapeutics price target lowered to $15 from $20 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Actuate Therapeutics (ACTU) to $15 from $20 and keeps a Buy rating on the shares. The firm adjusted the…
Actuate Therapeutics Proxy statement: Proxy filing
Actuate Therapeutics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Actuate Therapeutics Proxy statement: Proxy filing
Actuate Therapeutics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Actuate Therapeutics Annual report: Q4 2025
Actuate Therapeutics has published its Q4 2025 annual report on March 26, 2026.
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing ...
Actuate launches research initiative to combine elraglusib, RAS inhibitors
Actuate Therapeutics (ACTU) announced the launch of an expanded research initiative evaluating combinations of its clinical-stage GSK-3beta inhibitor elraglusib with emerging RAS-targeted therapies. D...
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
CHICAGO and FORT WORTH, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developi...